The effect of dapagliflozin in patients with type 2 diabetes mellitus in combination with hypertension and obesity
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to determine the effect of 6 months therapy with a new class of glucose lowering drugs – a sodium glucose cotransporter type 2 inhibitor dapagliflozin on glycemic control, body weight, blood pressure in patients with diabetes mellitus 2 type in combination with essential hypertension and obesity.
Patients and methods. The 36 patients with type 2 diabetes mellitus, hypertension and obesity were examined. Dapagliflozin in the dose of 10 mg was used in the complex therapy
Results. The results of the study showed that drugs in a combination therapy provided the glycemic control, led to the decrease of body mass index by 7,6% (р<0,05), that proves its advantage in the presence of overweight or obesity. The use of the drug has not led to the correction of lipid imbalances.
Conclusion.The results of the daily blood pressure monitoring indicate that dapagliflozin has antihypertensive activity, that confirms the reasonability of its use in patients with type 2 diabetes mellitus in combination with essential hypertension and obesity.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Дедов И.И. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / И.И. Дедов, М.В. Шестакова, Г.Р. Галстян // Сахарный диабет. – 2015. – Т. 18, No 1S – C. 1–12.
Маньковский Б.Н. Терапия сахарного диабета 2 типа: нереализованные потребности и новые возможности / Б.Н. Маньковский // Діабет. Ожиріння. Метаболічний синдром. – 2014. – No 4 (ІІІ). – С. 37–41.
Ушкалова Е.А. Новый класс антидиабетических препаратов – ингибиторы натрий глюкозных котранспортеров /Е.А. Ушкалова // Фарматека. – 2013. – No 16. – С. 33–36.
Филиппова И. Прогностическое значение ранней диагностики сахарного диабета / И. Филиппова // Ремедиум. – 2014. – No 3. – С. 65–75.
Шварц В.Я. Новый принцип лечения сахарного диабета 2-го типа путем стимуляции глюкозурии /В.Я. Шварц // Проблемы эндокринологии. – 2012. – Т. 58, No 4. – С. 54–57.
American Diabetes Association. Standards of Medical Care in Diabetes – 2013 // Diabetes Care. – 2013. – Vol. 36 (Suppl 1). – P. S11–S66.
Dedov I.I. Study design and methodology of an epidemiological survey to assess the prevalence of type 2 diabetes in Russia: NATION / I.I. Dedov, M.V. Shestakova, G.R. Galstyan //IDF. – 2015. – Poster 619.
Gyberg V. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology / V. Gyberg, D. De Bacquer, G. De Backer // Cardiovasc. Diabetol. – 2015. – Vol. 14. – P. 133.
Komoroski B. Dapagliflozin, a novel SGLT2 inhibitor, induces dose deen dent glucosuria in healthy subjects / B. Komoroski, N. Vachharajani, D. Boulton // Clin. Pharmacol. Ther. – 2015. – Vol. 85. – P. 520–526.
Nisly S.A. Canagliflozin, a new sodium glucose cotransporter 2 inhibitor, in the treatment of diabetes / S.A. Nisly, D.M. Kolanczyk, A.M. Walton // Am. J. Health Syst. Pharm. – 2013. – Vol. 70 (4). – P. 11–19.
Shah N.K. Dapagliflozin: a novel sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus / N.K. Shah, W.E. Deeb, R. Choksi // Pharmacotherapy. – 2012. – Vol. 32 (1). – P. 80–94.
Wandell P.E. Gender differences and time trends in incidence and prevalence of type 2 diabetes in Sweden a model explaining the diabetes epidemic world wide today / P.E. Wandell, A.C. Carlsson // Diabetes Res. Clin. Pract. – 2014. – Vol. 106 (3). – P. 18–24.
ESH/ESC Guidelines for the management of arterial hypertension // European Heart Journal. – 2013. – Vol. 34 (28). – P. 2159–2219.
